Advances in PSMA-Targeted PET Imaging for Prostate Cancer

Expert panelists review the evolving roles of PSMA-targeted PET imaging and conventional imaging in patients with prostate cancer.

EP1: Patient Risk Stratification and Evolving Imaging Modalities in Prostate Cancer

November 7th 2022

Expert panelists review risk stratification strategies for patients with prostate cancer and summarize the evolving use of conventional versus newer imaging modalities for diagnosis, treatment selection, and monitoring of these patients.

EP2: Prostate-Specific Membrane Antigen and its Relevance as a Target in Prostate Cancer Imaging and Treatment

November 7th 2022

A focused discussion on prostate-specific membrane antigen (PSMA) as a target for imaging and treatment for patients with prostate cancer.

EP3: Incorporating Newer Imaging Modalities Into Clinical Practice and Considerations for Nomenclature

November 14th 2022

Panelists consider how they have incorporated some newer imaging modalities, including PSMA-PET, into their clinical practice, and discuss the terminology that urologists and radiologists have recently used to describe these modalities.

EP4: A Review of FDA-Approved PSMA-PET Tracer Options

November 14th 2022

Radiologist Gary Ulaner, MD, PhD, FACNM provides a comprehensive discussion on the FDA-approved PSMA radiotracer options that are available for use as part of PSMA-PET imaging.

EP5: Benefits and Limitations of PSMA-PET Versus Earlier Imaging Modalities

November 21st 2022

Urologist Ashley Ross, MD, PhD leads a discussion of the benefits and limitations of PSMA-PET in patients with prostate cancer, as compared to older imaging modalities.

EP6: Sequencing of Conventional and PSMA-PET Imaging in Prostate Cancer

November 21st 2022

Citing recent guidelines recommendations, urologists share how they approach sequencing of conventional and PSMA-PET imaging for patients with prostate cancer, and discuss how use of each modality might affect subsequent patient management and treatment decisions.